Claims for Patent: 8,529,943

Summary for Patent: 8,529,943

Title:	Angiopoietin derived peptides
Abstract:	Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.
Inventor(s):	Kliger; Yossef (Rishon Le Zion, IL), Borukhov; Itamar (Ramat Hasharon, IL), Levy; Ofer (D.N Shimshon, IL), Tiran; Zohar (Oranit, IL), Wool; Assaf (Kiryat Ono, IL), Schreiber; Ehud (Ramat Gan, IL), Amir; Anat (D.N. Negev, IL), Levine; Zurit (Herzliya, IL), Toporik; Amir (Pardess Channa, IL)
Assignee:	Compugen Ltd. (Tel-Aviv, IL)
Application Number:	13/054,914
Patent Claims:	1. An isolated peptide consisting essentially of an amino acid sequence selected from the group consisting of an amino acid sequence as set forth in any one of SEQ ID NO: 10, or a homolog or a derivative thereof, wherein said peptide has anti-angiogenic activity, said peptide having at most 32 amino acids. 2. The isolated peptide according to claim 1, wherein said homolog is selected from the group consisting of the amino acid sequence as set forth in SEQ ID NOs. 134-136. 3. A fusion protein comprising the peptide of claim 1 fused to an immunoglobulin molecule. 4. The protein of claim 3, wherein the peptide is fused to an Fc fragment. 5. A pharmaceutical composition comprising the peptide according to claim 1 and a pharmaceutically acceptable carrier. 6. A pharmaceutical composition comprising the peptide according to claim 2 and a pharmaceutically acceptable carrier. 7. A method of treating or preventing an ocular disease in a subject in need thereof comprising administering the pharmaceutical composition according to claim 5 to said subject. 8. The pharmaceutical composition according to claim 5 wherein the pharmaceutically acceptable carrier is a controlled release vehicle, selected from the group consisting of biocompatible polymers, other polymeric matrices, capsules, microcapsules, nanocapsules, microparticles, nanoparticles, microspheres, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres and transdermal delivery systems, implantable or not. 9. The method of claim 7, wherein said ocular disease is an angiogenesis-related ocular disease. 10. The method according to claim 9, wherein the ocular disease is selected from the group consisting of retinal angiogenesis disorder, ocular neovascularisation, retinopathy, age-related macular degeneration, macular oedema, trachoma and corneal neovascularization. 11. The method according to claim 7, further comprising administering an additional therapeutic agent. 12. The method according to claim 11, wherein the additional therapeutic agent is an anti-angiogenic antibody. 13. The method according to claim 12, wherein said anti-angiogenic antibody is selected from the group consisting of bevacizumab and erbitux. 14. The method according to claim 5, wherein administering comprises topical or transdermal administration of the pharmaceutical composition in a formulation selected from the group consisting of an ointment, a paste, a cream, a lotion, an emulsion, a gel, a powder, a solution, a spray, an inhalant and a patch. 15. The isolated peptide of claim 1, wherein said peptide inhibits binding of Tie2 to an angiogenic protein. 16. The isolated peptide of claim 15, wherein said angiopoietin is selected from the group consisting of angiopoietin 1, angiopoetin 2 and angiopoietin 4. 17. The isolated peptide of claim 1, wherein said peptide inhibits in-ovo angiogenesis in the chorio-allantoic membranes of a fertilized egg.

Details for Patent 8,529,943

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2028-07-21
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2028-07-21
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2028-07-21